

# Person with cancer— castrate resistance date, DDMMYYYY

## Identifying and definitional attributes

<b>Metadata item type:</b>	Data Element
<b>Short name:</b>	Castrate resistance date
<b>METEOR identifier:</b>	492865
<b>Registration status:</b>	<ul style="list-style-type: none"><li>• <a href="#">Health</a>, Standard 14/05/2015</li></ul>
<b>Definition:</b>	The date on which two consecutive rising prostate-specific antigen (PSA) levels were found despite castrate levels of testosterone in a person with cancer, expressed as DDMMYYYY.
<b>Data Element Concept:</b>	<a href="#">Person with cancer—castrate resistance date</a>

## Value domain attributes

## Representational attributes

<b>Representation class:</b>	Date
<b>Data type:</b>	Date/Time
<b>Format:</b>	DDMMYYYY
<b>Maximum character length:</b>	8

## Data element attributes

## Collection and usage attributes

<b>Guide for use:</b>	<p>Where two consecutive rising prostate-specific antigen levels (PSA) were found despite castrate levels of testosterone (&lt;50ng/dL), record the date of the second test.</p> <p>For a person to be recorded as castrate resistant, PSA tests need to be at least two weeks apart and both must be higher than the test prior.</p> <p>This element should be recorded in conjunction with the <a href="#">Castrate resistance indicator</a> item.</p>
-----------------------	--

## Source and reference attributes

<b>Submitting organisation:</b>	Cancer Australia
---------------------------------	------------------

**Reference documents:** National Comprehensive Cancer Network 2013. NCCN Guidelines in Oncology: Prostate Cancer Version 2.2013. National Comprehensive Cancer Network, Fort Washington

Scher HI Halabi S Tannock I et al 2008. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. Journal of Clinical Oncology 26: 1148-54

## Relational attributes

**Related metadata references:** See also [Person with cancer—castrate resistance indicator, yes/no code N](#)

- [Health](#), Standard 14/05/2015

**Implementation in Data Set Specifications:**

[Prostate cancer \(clinical\) NBPDS](#)  
[Health](#), Standard 14/05/2015

***Conditional obligation:***

Collect this item when [Person with cancer—castrate resistance, yes/no code N](#) equals yes.

© Australian Institute of Health and Welfare 2015–2023

This product, excluding the AIHW logo, Commonwealth Coat of Arms and any material owned by a third party or protected by a trademark, has been released under a Creative Commons BY 3.0 (CC BY 3.0) licence. Excluded material owned by third parties may include, for example, design and layout, images obtained under licence from third parties and signatures. We have made all reasonable efforts to identify and label material owned by third parties.

You may distribute, remix and build upon this work. However, you must attribute the AIHW as the copyright holder of the work in compliance with our attribution policy available at [www.aihw.gov.au/copyright](http://www.aihw.gov.au/copyright). The full terms and conditions of this licence are available at <http://creativecommons.org/licenses/by3.0/au/>.

Enquiries relating to copyright should be addressed to the Head of the Communications, Media and Marketing Unit, Australian Institute of Health and Welfare, GPO Box 570, Canberra ACT 2601.